Daito Pharmaceutical Co., Ltd.
4577ダイト株式会社
Latest half-year results
First half · fiscal year to 2026-05 · filed 2026-01-14For the first half of the fiscal year to 2026-05: Revenue ¥25.1 billion (+2.3% YoY), Ordinary income ¥1.8 billion (+20.0% YoY), Net income ¥1.2 billion (+35.8% YoY).
| This period | Year on year | |
|---|---|---|
| Revenue | ¥25.1bn | +2.3% |
| Ordinary profit | ¥1.8bn | +20.0% |
| Net profit to owners | ¥1.2bn | +35.8% |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4577/earnings-releases.
Financials
Japan GAAP · consolidated · fiscal year to 2026-05-31- Revenue
- ¥50.7bn
- Net income
- ¥3.2bn
- ROE
- 6.0%
- Equity ratio
- 72.2%
- Dividend / share
- ¥40
- Employees
- 1,085
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2026-05-31 | ¥50.7bn | ¥3.2bn | ¥73.3bn | ¥52.9bn | 6.0% | ¥107.49 | ¥9.4bn |
| 2025-05-31 | ¥50.6bn | ¥1.9bn | ¥78.0bn | ¥52.1bn | 3.7% | ¥62.74 | ¥5.9bn |
| 2024-05-31 | ¥46.9bn | ¥3.3bn | ¥77.7bn | ¥52.3bn | 6.4% | ¥105 | ¥5.2bn |
| 2023-05-31 | ¥45.1bn | ¥3.6bn | ¥70.6bn | ¥51.0bn | 7.3% | ¥113.81 | ¥4.2bn |
| 2022-05-31 | ¥43.5bn | ¥4.7bn | ¥64.9bn | ¥47.7bn | 10.5% | ¥152.46 | ¥4.4bn |
Indicators
Computed by us from filings · fiscal year to 2026-05-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | 6 | 31.9 |
| Ordinary margin | 0.0753 | 54.2 |
| Equity ratio, % | 72.2 | 78.4 |
| Revenue growth | 0.0001 | 24.9 |
| Net income growth | 0.6567 | 79.5 |
| Operating cash flow / assets | 0.1279 | 84.2 |
Results wording balance: 0.00. Proprietary text method; it describes the wording only and does not interpret context.
Interest example: if all ¥6.6bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥33m, 0.3% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.
Via /v1/companies/4577/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states them/v1/companies/4577/buybacksSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4577/votingOwnership changes
All companies →- 2026-10-13
Kaname Capital, L.P. raised holdings in Daito Pharmaceutical Co., Ltd. (4577) to 12.13% from 11.13%.
- 2026-02-04
Massachusetts Financial Services Company cut holdings in Daito Pharmaceutical Co., Ltd. (4577) to 3.91% from 5.05%, below the 5% threshold.
- 2025-09-05
Kaname Capital, L.P. raised holdings in Daito Pharmaceutical Co., Ltd. (4577) to 11.13% from 9.98%.
- 2025-09-05
Holdings of Kaname Capital, L.P. in Daito Pharmaceutical Co., Ltd. (4577) moved above 10% (9.98% -> 11.13%).
- 2025-08-15
Kaname Capital, L.P. filed a correction to a 5% report on Daito Pharmaceutical Co., Ltd. (4577).
- 2024-08-22
Kaname Capital, L.P. raised holdings in Daito Pharmaceutical Co., Ltd. (4577) to 9.98% from 8.96%.
- 2024-06-26
Kaname Capital, L.P. raised holdings in Daito Pharmaceutical Co., Ltd. (4577) to 8.96% from 7.84%.
- 2024-05-07
Kaname Capital, L.P. raised holdings in Daito Pharmaceutical Co., Ltd. (4577) to 7.84% from 6.72%.
- 2024-04-17
Kaname Capital, L.P. filed a correction to a 5% report on Daito Pharmaceutical Co., Ltd. (4577).
- 2024-03-25
Kaname Capital, L.P. raised holdings in Daito Pharmaceutical Co., Ltd. (4577) to 6.78% from 5.63%.
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| Kaname Capital,L.P. | 2026-09-04 – 2026-10-02 | +72,600 | +0.25pt | — | — |
| Highclere International Investors LLP | 2023-05-19 – 2023-07-07 | -116,100 | −0.81pt | — | — |
| 大和証券株式会社 | 2021-10-18 – 2021-12-14 | -98,200 | −0.67pt | — | — |
| 大和アセットマネジメント株式会社 | 2021-10-19 – 2021-10-28 | +400 | 0.00pt | ¥3,247.5 | ¥3,175–3,320 |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4577/trades.
5% filings
Large shareholding reports on 4577| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-10-13 | Kaname Capital, L.P. | 12.13% | +1.00pt | pure investment |
| 2026-02-04 | Massachusetts Financial Services Company | 3.91% | −1.14pt | pure investment |
| 2025-09-05 | Kaname Capital, L.P. | 11.13% | +1.15pt | pure investment |
| 2025-08-15 | Kaname Capital, L.P. | 11.13% | +1.15pt | pure investment |
| 2025-06-06 | Kaname Capital, L.P. | 9.98% | 0.00pt | pure investment |
| 2024-08-22 | Kaname Capital, L.P. | 9.98% | +1.02pt | pure investment |
| 2024-06-26 | Kaname Capital, L.P. | 8.96% | +1.12pt | pure investment |
| 2024-05-07 | Kaname Capital, L.P. | 7.84% | +1.12pt | pure investment |
| 2024-04-17 | Kaname Capital, L.P. | 6.72% | +1.09pt | pure investment |
| 2024-03-25 | Kaname Capital, L.P. | 6.78% | +1.15pt | pure investment |
Cross-shareholdings
From the annual report's status of shareholdings- Listed strategic holdings
- 20 issues
- Book value
- ¥2.0bn
- Sold in the year
- ¥454m 8 issues
- Bought in the year
- — — issues
- Mutual, both reports
- 7
- Held by listed cos.
- 9
| Holds | Book value | Shares vs. prior year | Mutual |
|---|---|---|---|
| THE FIRST BANK OF TOYAMA, LTD. 7184 | ¥452m | 0.0% | stated |
| Takeda Pharmaceutical Company Limited 4502 | ¥312m | 0.0% | no |
| DAIICHI SANKYO COMPANY, LIMITED 4568 | ¥238m | 0.0% | no |
| ONO PHARMACEUTICAL CO., LTD. 4528 | ¥191m | 0.0% | both reports |
| KAKEN PHARMACEUTIAL CO., LTD. 4521 | ¥165m | 0.0% | both reports |
| TOWA PHARMACEUTICAL CO.,LTD. 4553 | ¥119m | 0.0% | both reports |
| Riken Vitamin Co., Ltd. 4526 | ¥109m | 0.0% | no |
| SAWAI GROUP HOLDINGS Co., Ltd. 4887 | ¥100m | 0.0% | both reports |
| ASKA Pharmaceutical Holdings CO., Ltd. 4886 | ¥58m | 0.0% | both reports |
| Fuso Pharmaceutical Industries,Ltd. 4538 | ¥45m | 0.0% | stated |
Held by: ONO PHARMACEUTICAL CO., LTD. 4528, SAWAI GROUP HOLDINGS Co., Ltd. 4887, KAKEN PHARMACEUTIAL CO., LTD. 4521, TOWA PHARMACEUTICAL CO.,LTD. 4553, ASKA Pharmaceutical Holdings CO., Ltd. 4886, ASAHI PRINTING CO.,LTD. 3951, DAIICHI JITSUGYO CO., LTD. 8059, The Fukui Bank, Ltd. 8362, DAI-DAN CO.,LTD. 1980
Purposes, all holdings and mutual flags via /v1/companies/4577/cross-holdings. Share changes include stock splits.
Major shareholders
As of fiscal year end 2026-05-31| Shareholder | Shares | Ratio |
|---|---|---|
| 株式会社日本カストディ銀行(投資信託口) | 2,934,600 | 10.18% |
| JAPAN ABSOLUTE VALUE FUND | 2,688,300 | 9.32% |
| 日本マスタートラスト信託銀行株式会社(管理有価証券信託口) | 1,770,500 | 6.14% |
| 日本マスタートラスト信託銀行株式会社(投資信託口) | 1,258,100 | 4.36% |
| individual holder | 1,000,000 | 3.47% |
| 株式会社オオツガ | 800,600 | 2.78% |
| individual holder | 694,214 | 2.41% |
| 二幸商事株式会社 | 640,000 | 2.22% |
| individual holder | 615,000 | 2.13% |
| ダイト従業員持株会 | 495,774 | 1.72% |
U.S. funds holding 4577
SEC Form N-PORT, reports to 2026-07-3135 U.S. funds held 1,985,455 shares worth $15.4m.
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND VANGUARD STAR FUNDS | 373,382 | $2.9m | 0.000% | 2026-07-31 |
| DFA INTERNATIONAL SMALL CAP VALUE PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 248,164 | $1.9m | 0.014% | 2026-07-31 |
| VANGUARD DEVELOPED MARKETS INDEX FUND VANGUARD TAX-MANAGED FUNDS | 217,800 | $1.7m | 0.001% | 2026-06-30 |
| Dimensional International Small Cap Value ETF Dimensional ETF Trust | 164,453 | $1.3m | 0.026% | 2026-07-31 |
| Avantis International Small Cap Value ETF American Century ETF Trust | 154,300 | $1.2m | 0.006% | 2026-05-31 |
Up to 25 funds per stock via the API.
Get this as JSON
GET /v1/companies/4577
GET /v1/companies/4577/financials
GET /v1/companies/4577/details
GET /v1/companies/4577/segments
GET /v1/companies/4577/voting
GET /v1/companies/4577/tender-offers
GET /v1/companies/4577/indicators
GET /v1/companies/4577/earnings-releases
GET /v1/events?ticker=4577
GET /v1/companies/4577/trades
GET /v1/companies/4577/cross-holdings
GET /v1/companies/4577/brief